Skip to main content
. 2017 Jan 18;8(8):13253–13263. doi: 10.18632/oncotarget.14710

Figure 6. miR-625 targets the 3′-UTR of SOX2.

Figure 6

A-B. The putative binding sites of miR-625 in the SOX2 3′-UTR region were predicted by miRanda.org and TargetScan.org. The matched seed sequences are indicated by vertical lines. C. Relative expression of SOX2 in malignant melanoma patients’ tumor tissues compared with normal tissues. Data are shown as mean ± SEM (*P < 0.05). D. Linear correlation analysis of SOX2 and miR-625 expression in melanoma samples. E. Schematic graph of the putative binding sites of miR-625 in the SOX2 3′UTR and the mutation in miR-625 binding sites. F. miR-625 mimics downregulated luciferase activities controlled by wild-type SOX2 3′UTR, but did not affect luciferase activity controlled by mutant SOX2 3′UTR. The results are means of three independent experiments ± S.D. (*P < 0.05).